The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer
Official Title: A Randomized, Multicenter, Open-label, Phase III Study of Lapatinib (GW572016) in Combination With Weekly Paclitaxel Versus Weekly Paclitaxel Alone in the Second Line Treatment of ErbB2 Amplified Advanced Gastric Cancer
Study ID: NCT00486954
Brief Summary: EGF104578 is two-part study (Pilot part/Randomized part).Pilot part is designed to find the optimal (best) doses of lapatinib and paclitaxel when given together,Randomized part is designed to evaluate the overall survival in patients receiving lapatinib and paclitaxel compared to patients receiving only paclitaxel.
Detailed Description:
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
GSK Investigational Site, Guangzhou, Guangdong, China
GSK Investigational Site, Beijing, , China
GSK Investigational Site, Beijing, , China
GSK Investigational Site, Shanghai, , China
GSK Investigational Site, Tokyo, , Japan
GSK Investigational Site, Hwasun, , Korea, Republic of
GSK Investigational Site, Seongnam-si Gyeonggi-do, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Kaohsiung, , Taiwan
GSK Investigational Site, Niaosong Township, Kaohsiung, , Taiwan
GSK Investigational Site, Tainan County, , Taiwan
GSK Investigational Site, Tainan, , Taiwan
GSK Investigational Site, Taipei, , Taiwan
GSK Investigational Site, Taipei, , Taiwan
GSK Investigational Site, Tau-Yuan County, , Taiwan
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR